Astria Therapeutics will launch a new study to assess the safety, tolerability, activity, pharmacokinetics, pharmacodynamics, and immunogenicity of STAR-0215, a novel therapy for patients with hereditary angioedema (HAE).

The phase 1b/2, interventional, single- and multiple-dose, nonrandomized study is expected to start in February 2023 and will enroll 18 adult participants with type 1 or 2 HAE.

The participants will be divided into 2 dose cohorts; one will receive a single subcutaneous dose of STAR-0215 and the other will receive 2 subcutaneous doses 3 months apart. The primary outcome measure will be the number of participants with treatment-emergent adverse effects.

Explore more great content on Hereditary Angioedema (HAE) →
The Pathophysiology and Clinical Manifestations of Hereditary Angioedema
The Challenges of Diagnosing and Managing Hereditary Angioedema
Hereditary Angioedema Often Impacts Patients’ Reproductive Decisions
Continue Reading

Secondary outcome measures include changes from baseline in HAE attack rate (per month), severity and duration of attacks, time interval to attacks after STAR-0215 dosing, serum concentrations of STAR-0215, plasma kininogen levels, and the number of participants with antidrug antibodies.

Read more about HAE therapies

Hereditary angioedema is a genetic condition caused by a mutation in the SERPING1 gene, which codes for C1-inhibitor (C1-INH), and it is characterized by repeated swelling episodes, particularly in the face, limbs, airway, and intestinal tract. HAE is caused by an absence or deficiency of C1-INH, and is classified as type 1, which is due to a reduced quantity of C1-INH, and type 2, which is caused by dysfunctional C1-INH protein. A third type has recently been identified in which patients have normal C1-INH.  

STAR-0215 is a monoclonal antibody inhibitor of plasma kallikrein, with the aim of sustained prevention of HAE attacks. A phase 1a trial of the therapy showed rapid and long-lasting kallikrein inhibition for up to 110 days in healthy volunteers. The results revealed the potential for dosing once every 3 months or even less frequently, which will be assessed in upcoming studies.

The new study is expected to deliver preliminary results in mid-2024. Astria also plans to assess the potential for 6-month dosing of STAR-0215 in another phase 1a trial expected to start in the first quarter of 2023.    

Reference 

A study of STAR-0215 in participants with hereditary angioedema. ClinicalTrials.gov. January 23, 2023. Accessed January 27, 2023.          

Astria Therapeutics Gastroenterologists immunologists STAR-0215